In a CLP mouse model, the HDAC6 inhibitor, Tubastatin A, was shown to restore B lymphocyte percentage, as well as other innate immune cells, to improve sepsis prognosis [121], which suggests the potential role of histone deacetylation to B cell down-regulation in sepsis. The gene discussed is HDAC6; the disease is Sepsis.